1Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut, 2006, 55: 1-15.
2American Gastroenterological Association Institute. American Gastroenterological Association Institute medical statement on corticosteroids, immunomodulators, and infliximab in inflammato ry bowel disease. Gastroenterology, 2006, 130:935-939.
3Hanauer SB, Feagan BG, Lichtenstein GR. et al. Maintenance infliximab for Crohn's disease: the ACCENT Ⅰ randomized trial. Lancet, 2002, 359 (9317): 1541-1549.
4Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mueosal ulceration associated with Crohn's disease. Gastrointest Endosc, 2006, 63:433-442.
5Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther, 2006, 23:451-463.
6Belaiche J, Louis E, D'Haens G, et al. Acute lower gastrointestinal bleeding in Crohn's disease: characteristics of a unique series of 34 patients. Am J Gastroenterol, 1999,94: 2177-2181.
7Papi C, Gili L, Tarquini M, et al. Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage. J Clin Gastroenterol, 2003,36 : 238-241.
8Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ, Alexan- der GL, Balm RK, Gostout CJ. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endosc 1999; 49:153-157.
9Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn's disease. Ann Surg 1991; 213:207-211.
10Belaiche J, Louis E, D'Haens G, Cabooter M, Naegels S, De Vos M, Fontaine F, Schurmans P, Baert F, De Reuck M, Fiasse R, Holvoet J, Schmit A, Van Outryve M. Acute lower gastrointestinal bleeding in Crohn's disease: characteris- tics of a unique series of 34 patients. Belgian IBD Research Group. Am J Gastroentero11999; 94:2177-2181.
